eCite Digital Repository

The host microbiome and impact of tuberculosis chemotherapy


O'Toole, R and Gautam, SS, The host microbiome and impact of tuberculosis chemotherapy, Tuberculosis, 113 pp. 26-29. ISSN 1472-9792 (2018) [Refereed Article]

Copyright Statement

2018 Elsevier Ltd

DOI: doi:10.1016/


The treatment of Mycobacterium tuberculosis infection is often viewed in isolation from other human microbial symbionts. Understandably, the clinical priority is eliminating active or latent tuberculosis (TB) in patients. With the increasing resolution of molecular biology technologies, it is becoming apparent that antibiotic treatment can perturb the homeostasis of the host microbiome. For example, dysbiosis of the gut microbiota has been associated with an increased risk of the development of asthma, obesity and diabetes. Therefore, fundamental questions include: Does TB chemotherapy cause disruption of the human microbiome and adverse effects in patients; and are there signature taxa of dysbiosis following TB treatment. In this review, we examine recent research on the detection of changes in the microbiome during antibiotic administration and discuss specific findings that relate to the impact of anti-tubercular chemotherapy.

Item Details

Item Type:Refereed Article
Keywords:Mycobacterium tuberculosis, microbiome, antibiotic
Research Division:Biomedical and Clinical Sciences
Research Group:Medical microbiology
Research Field:Medical bacteriology
Objective Division:Manufacturing
Objective Group:Human pharmaceutical products
Objective Field:Human pharmaceutical treatments
UTAS Author:O'Toole, R (Dr Ronan O'Toole)
UTAS Author:Gautam, SS (Mr Sanjay Gautam)
ID Code:128247
Year Published:2018
Web of Science® Times Cited:6
Deposited By:Medicine
Deposited On:2018-09-11
Last Modified:2019-12-03

Repository Staff Only: item control page